PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDYRandomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic control arm in second line treatment of metastatic neuroendocrine carcinoma of gastro-enteropancreatic or unknown origin.Phase II comparative randomized study – multicentric

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2025
This article has no abstract
Epistemonikos ID: 1cf79180dfd598fd5ec07f28b9b77294503362d3
First added on: Apr 24, 2026